• Gilead Sciences Inc., of Foster City, Calif., said the European Commission granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor to treat HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.